Safety of Abiraterone Acetate Administration in Elderly Patients Receiving Peritoneal Dialysis with Castration-Resistant Prostate Cancer: Two Case Reports.
We report two elderly patients receiving peritoneal dialysis with castration-resistant prostate cancer (CRPC). Herein, we show that the patients were safely treated using abiraterone acetate (750 mg/day orally once daily) and prednisolone (5 mg/day orally once daily). Although the prostate-specific antigen (PSA) level increased in both cases, there was no manifestation of disease progression (clinical and radiographic) for 22 months in case 1 and 8 months in case 2. In case 2, the only adverse event was hypokalemia, which was treated using potassium preparations.
PMID: 31130566 [PubMed - in process]
Source: Journal of Nippon Medical School - Category: Universities & Medical Training Authors: Kimata R, Tomita Y, Kondo Y Tags: J Nippon Med Sch Source Type: research
More News: Abiraterone Acetate | Cancer | Cancer & Oncology | Dialysis | Japan Health | Peritoneal Dialysis | Potassium | Prednisolone | Prostate Cancer | Radiography | Science | Universities & Medical Training